181 related articles for article (PubMed ID: 38302412)
1. FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer.
Li H; Zheng N; Guo A; Tang W; Li M; Cao Y; Ma X; Cao H; Ma Y; Wang H; Zhao S
Cell Death Dis; 2024 Feb; 15(2):107. PubMed ID: 38302412
[TBL] [Abstract][Full Text] [Related]
2. Follistatin-Like 3 Correlates With Lymph Node Metastasis and Serves as a Biomarker of Extracellular Matrix Remodeling in Colorectal Cancer.
Yang C; Cao F; Huang S; Zheng Y
Front Immunol; 2021; 12():717505. PubMed ID: 34335633
[TBL] [Abstract][Full Text] [Related]
3. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
[TBL] [Abstract][Full Text] [Related]
4.
Fong W; Li Q; Ji F; Liang W; Lau HCH; Kang X; Liu W; To KK; Zuo Z; Li X; Zhang X; Sung JJ; Yu J
Gut; 2023 Nov; 72(12):2272-2285. PubMed ID: 37770127
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer.
Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
[TBL] [Abstract][Full Text] [Related]
6. GITR Ligation Improves Anti-PD1-Mediated Restoration of Human MMR-Proficient Colorectal Carcinoma Tumor-Derived T Cells.
Rakké YS; Campos Carrascosa L; van Beek AA; de Ruiter V; van Gemerden RS; Doukas M; Doornebosch PG; Vermaas M; Ter Borg S; van der Harst E; Coene PPLO; Kliffen M; Grünhagen DJ; Verhoef C; IJzermans JNM; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2023; 15(1):77-97. PubMed ID: 36155259
[TBL] [Abstract][Full Text] [Related]
7. CXCL10 mediates CD8
Yan W; Qiu L; Yang M; Xu A; Ma M; Yuan Q; Ma X; Liang W; Li X; Lu Y
Cancer Lett; 2023 Jul; 567():216263. PubMed ID: 37354983
[TBL] [Abstract][Full Text] [Related]
8. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
10. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
11. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
Kitsou M; Ayiomamitis GD; Zaravinos A
Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of PD‑L1 in colorectal cancer (Review).
Ntomi V; Foukas P; Papaconstantinou D; Antonopoulou I; Pikoulis A; Panagiotides I; Pikoulis E; Syrigos K
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846789
[TBL] [Abstract][Full Text] [Related]
13. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8
Cagnoni AJ; Giribaldi ML; Blidner AG; Cutine AM; Gatto SG; Morales RM; Salatino M; Abba MC; Croci DO; Mariño KV; Rabinovich GA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006646
[TBL] [Abstract][Full Text] [Related]
14. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
Ngiow SF; Young A; Jacquelot N; Yamazaki T; Enot D; Zitvogel L; Smyth MJ
Cancer Res; 2015 Sep; 75(18):3800-11. PubMed ID: 26208901
[TBL] [Abstract][Full Text] [Related]
15. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
16. MGP promotes CD8
Rong D; Sun G; Zheng Z; Liu L; Chen X; Wu F; Gu Y; Dai Y; Zhong W; Hao X; Zhang C; Pan X; Tang J; Tang W; Wang X
Int J Biol Sci; 2022; 18(6):2345-2361. PubMed ID: 35414780
[TBL] [Abstract][Full Text] [Related]
17. CHSY1 promotes CD8
Sun G; Zhao S; Fan Z; Wang Y; Liu H; Cao H; Sun G; Huang T; Cai H; Pan H; Rong D; Gao Y; Tang W
J Exp Clin Cancer Res; 2023 Sep; 42(1):248. PubMed ID: 37749638
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
20. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
